Pharmacokinetics of standard dose regimens of rifampicin in patients with pulmonary tuberculosis in Pakistan

Scandinavian Journal of Infectious Diseases

Volumn 44, Issue 6, 2012, Pages 459-464

  Shaheen, Abida ^a   Najmi, Muzammil Hasan ^a   Saeed, Waseem ^b   Farooqi, Zia Ur Rehman ^c  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

^b Military Hospital   (Pakistan)

^c ARMY MEDICAL COLLEGE   (Pakistan)

Author keywords

HPLC; Pharmacokinetics; Pulmonary tuberculosis; Rifampicin

Indexed keywords

ETHAMBUTOL; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LUNG TUBERCULOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; PAKISTAN; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTITUBERCULAR AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; PAKISTAN; PLASMA; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 84861611828     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2011.647832     Document Type: Article

References (33)

1. World Health Organization. Global tuberculosis control: WHO report 2010. WHO/HTM/TB/2010.7. Geneva: WHO; 2010.
2. World Health Organization. Global tuberculosis control: surveillance, planning, fi nancing. WHO report 2008. WHO/ HTM/TB/2008.393. Geneva: WHO; 2008.
3. Mitchison DA. The Garrod Lecture. Understanding the chemotherapy of tuberculosis - current problems. J Antimicrob Chemother 1992;29:477-93.
4. Loos U, Musch E, Jense JC, Mikus G, Schwabe HK, Eichelbaum M. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 1985;63:1205-11.
5. Zhang JN, Liu XG, Zhu M, Chiu FC, Li RC. Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing. J Chemother 1998;10:354-9.
6. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001;344:1294-303.
7. Cavenaghi R. Rifampicin raw material characteristics and their effect of bioavailability. Bull Int Union Tuberc Lung Dis 1989;64:36-7.
8. Seigler DI, Bryant M, Burley DM, Citron M, Standen SM. Effect of meals on rifampicin absorption. Lancet 1974; 2:197-8.
9. Boman G, Lundgren P, Stjernströ m G. Mechanism of the inhibitory effect of PAS granules on the absorption of rifampicin. Adsorption of rifampicin by an excipient, bentonite. Eur J Clin Pharmacol 1975;8:293-9.
10. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Adopted by the 18 th WMA General Assembly (1964) Helsinki, Finland and amended by the 59 th WMA General Assembly 2008, Seoul. WMA; 2008.
11. Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther 1997;61:544-53.
12. Panchagnula R, Sood A, Sharda N, Kau K, Kaul CL. Determination of rifampicin and its main metabolite in plasma and urine in presence of pyrazinamide and isoniazid by HPLC method. J Pharm Biomed Anal 1999;18:1013-20.
13. Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin Chest Med 1997;18:79-87.
14. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low serum antimycobacterial drug levels in non-HIV infected tuberculosis patients. Chest 1998;113: 1178-83.
15. Mehta JB, Shantaveerapa H, Byrd RP, Morton SE, Fountain F, Roy TM. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001;120:1520-4.
16. Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 2005;41:461-9.
17. Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, et al. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother 2008;52:2138-48.
18. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011;50: 99-110.
19. van Crevel R, Alisjahbana B, de Lange WC, Borst F, Danusantoso H, van der Meer JW, et al. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis 2002;6:497-502.
20. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006;50:1170-7.
21. Panchagnula R, Agrawal S. Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin. Int J Pharm 2004;271:1-4.
22. Sankar R, Sharda N, Singh S. Behaviour of decomposition of rifampicin in the presence of isoniazid in the pH range 1 - 3. Drug Dev Ind Pharm 2003;29:733-8.
23. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfi nger M, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007;51:3781-8.
24. Verbist L. Rifampicin activity ' i n vitro ' and in established tuberculosis in mice. Acta Tuberc Pneumol Belg 1969;60: 397-412.
25. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh B N, Jayashree R, et al. Pharmacokinetics - pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;47:2118-24.
26. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009;13:1320-30.
27. Long MW, Snider DE Jr, Farer LS. U.S. Public Health Service Cooperative trial of three rifampicin - isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119:879-94.
28. Sirgel FA, Fourie PB, Donald PR, Padayatchi N, Rustomjee R, Levin J, et al. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005;172:128-35.
29. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:939-49.
30. Goutelle S, Bourguignon L, Maire PH, Guilder MV, Conte Jr JE, Jelliffe RW. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother 2009;53:2974-81.
31. Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, et al. The early bactericidal activity of high-dose rifampin in patients with sputum smear positive pulmonary tuberculosis. Antimicrob Agents Chemother 2007;51:2994-6.
32. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983;5:S440 - 6.
33. Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology 2006;11:699-707.